[Metrizamide encephalopathy in a child with hydrocephalus--effects of L-threo-DOPS on persistent disturbance of consciousness and L-dopa on extrapyramidal symptoms].
This report describes a case of metrizamide encephalopathy with persistent disturbance of consciousness and extrapyramidal symptoms. These two conditions have rarely been reported among the various adverse effects of metrizamide. An 11-year-old girl had been in almost good health until she was ten years old, at which time she received a ventriculo-peritoneal shunt operation, suffering from hydrocephalus of unknown etiology. At the age of eleven, she was admitted to our hospital due to hydrocephalus recurrence. She was examined by metrizamide shunt-gram (1200 mg iodide/4 ml). On the next day, she became drowsy. The CT scan disclosed the periventricular penetration of metrizamide into the medial part of the thalamus and the caudate nucleus. Thirteen days later, disturbance of consciousness continued, and extrapyramidal symptoms, that is, rigo-spasticity and postural tremor, were observed. Oral administration of L-threo-DOPS, the direct precursor of noradrenaline, was effective against the persistent disturbance of consciousness and L-DOPA was effective against the extrapyramidal symptoms. She soon recovered almost to normal and no neurological deficit remained. We thus conclude that the CT scan findings and effects of L-threo-DOPS and L-DOPA suggest that metrizamide encephalopathy in this case were respectively due to its periventricular penetration into the medial part of the thalamus and the caudate nucleus, and the resultant deficiency of the ascending noradrenergic reticular activating system and the nigrostriatal dopaminergic system.
Usui
S
S
Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Komiya
T
T
Imai
H
H
Narabayashi
H
H
D001480:Basal Ganglia Diseases / Q000139:chemically induced* / Q000188:drug therapy; D001921:Brain / Q000000981:diagnostic imaging; D001927:Brain Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D002648:Child; D003072:Cognition Disorders / Q000139:chemically induced*; D003244:Consciousness Disorders / Q000139:chemically induced* / Q000188:drug therapy; D015103:Droxidopa / Q000627:therapeutic use*; D004569:Electroencephalography; D005119:Extravasation of Diagnostic and Therapeutic Materials; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000188:drug therapy* / Q000503:physiopathology; D007980:Levodopa / Q000627:therapeutic use*; D008793:Metrizamide / Q000009:adverse effects*; D012694:Serine / Q000031:analogs & derivatives*; D014057:Tomography, X-Ray Computed
D012694:Serine; D007980:Levodopa; D015103:Droxidopa; D008793:Metrizamide